Grima, Daniel T.; Thompson, Melissa F.; Sauriol, Luc - In: PharmacoEconomics 25 (2007) 3, pp. 253-266
Background and objective: Intensive insulin therapy improves glycosylated haemoglobin (HbA1C) levels and delays the onset of long-term diabetes-related complications. Current treatment guidelines recommend maintaining a glycosylated haemoglobin (HbA1C) of <=7% in patients with type 1 and 2 diabetes mellitus. However, the risk of hypoglycaemia increases with lower HbA1C levels. As such, patients often choose to settle for suboptimal glucose control in order to prevent hypoglycaemic events. At a given HbA1C level, treatment with insulin glargine results in a lower risk of hypoglycaemia in type 1 and 2 diabetes compared with NPH insulin. It has been proposed that the lower hypoglycaemic risk will allow more patients to achieve target HbA1C levels with insulin glargine compared with NPH insulin. The objective of this study was to assess the cost effectiveness of insulin glargine compared with NPH insulin in patients with type 1 or 2 diabetes who had inadequate glycaemic control. Methods: A long-term, state-transition model was developed to simulate the natural history of type 1 and 2 diabetes. Risks of diabetes-related macro- and microvascular complications and mortality by HbA1C levels were estimated based on the UKPDS (United Kingdom Prospective Diabetes Study). Outcome measures included complication rates and associated costs, insulin costs, life years (LYs) and QALYs. The baseline analysis was conducted for patients with type 1 and 2 diabetes (aged 27 and 53 years, respectively) with HbA1C levels >7%, using a 36-year time horizon and a...</=7%>
